Stockwatch: The Desert After The Bubble
This article was originally published in Scrip
After the controversies surrounding drug pricing and specialty pharmacy channel stuffing it is no wonder that we are in the lackluster period after the bursting of the 2015 biotech bubble. Traditionally the aftermath of burst stock market bubbles can be associated with years in the investment wilderness, where generalist investors mostly avoid the sector.
You may also be interested in...
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.